Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients

European Journal of Haematology, Supplement

Volumn 61, Issue 64, 2001, Pages 14-20

  Aurlien, E ^a   Holte, H ^a   Kvaloy S ^a   Jakobsen, E ^a   Rusten, L S ^a   Kvalheim, G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

CD34+ cells; Combination chemotherapy; Malignant lymphoma; MIME, G CSF; PSPC mobilization

Indexed keywords

CD34 ANTIGEN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOGUAZONE; ANTINEOPLASTIC AGENT; MIME PROTOCOL;

ADULT; CANCER RECURRENCE; CELL COUNT; CELL MIGRATION; CELL TRANSFORMATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL; ADOLESCENT; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; METHODOLOGY; MIDDLE AGED; PREMEDICATION; RECURRENT DISEASE; STANDARD; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; ETOPOSIDE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LYMPHOMA; METHOTREXATE; MIDDLE AGED; MITOGUAZONE; PREMEDICATION; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034743468     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
2. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma
3. The biology and clinical uses of blood stem cells
4. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor
5. Results of MIME salvage regimen for recurrent or refractory lymphoma
6. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: A Swedish national prospective study
7. Combination chemotherapy with mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
8. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients
9. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report from the second Nordic Workshop
10. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer
11. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma
12. 2 in patients with advanced cancer
13. Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: Timing of harvesting and composition of the leukapheresis product
14. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
15. Purging of tumor cells from leukapheresis products: Experimental and clinical aspects
16. + cells from peripheral blood progenitor cell products
17. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts